Law firm investigates Alnylam for potential securities fraud after revenue guidance cut and stock plunge.

Kirby McInerney LLP is investigating Alnylam Pharmaceuticals for possible securities fraud following the company's announcement of lowered 2026 sales guidance for its TTR product, reducing projected revenues by about $200 million. This revision led to a sharp 28% drop in Alnylam's stock price. The investigation aims to determine if Alnylam or its executives violated federal securities laws. No lawsuit has been filed yet, but investors who bought Alnylam shares are encouraged to contact the law firm for potential claims.